{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:54:20Z","timestamp":1788796460012,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.ejim.2015.01.005","type":"journal-article","created":{"date-parts":[[2015,1,26]],"date-time":"2015-01-26T20:33:02Z","timestamp":1422304382000},"page":"89-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Drug treatment of obesity: Current status and future prospects"],"prefix":"10.1016","volume":"26","author":[{"given":"Ashish Kumar","family":"Kakkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Dahiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2015.01.005_bb0005","author":"WHO | Obesity and overweight"},{"issue":"8","key":"10.1016\/j.ejim.2015.01.005_bb0010","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/jama.2014.732","article-title":"Prevalence of childhood and adult obesity in the United States, 2011\u20132012","volume":"311","author":"Ogden","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2015.01.005_bb0015","author":"Choices"},{"key":"10.1016\/j.ejim.2015.01.005_bb0020","author":"Foresight"},{"issue":"1","key":"10.1016\/j.ejim.2015.01.005_bb0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrendo.2012.199","article-title":"Global obesity: trends, risk factors and policy implications","volume":"9","author":"Malik","year":"2013","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.ejim.2015.01.005_bb0035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2458-9-88","article-title":"The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis","volume":"9","author":"Guh","year":"2009","journal-title":"BMC Public Health"},{"issue":"8","key":"10.1016\/j.ejim.2015.01.005_bb0040","doi-asserted-by":"crossref","first-page":"421-421","DOI":"10.1038\/ncpendmet0889","article-title":"Gastric banding to treat obesity: band-aid or breakthrough?","volume":"4","author":"Polonsky","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.ejim.2015.01.005_bb0045","author":"Practical Guide to the Identification"},{"key":"10.1016\/j.ejim.2015.01.005_bb0050","doi-asserted-by":"crossref","first-page":"179674","DOI":"10.1155\/2011\/179674","article-title":"Pharmacotherapies for obesity: past, current, and future therapies","volume":"2011","author":"Ioannides-Demos","year":"2011","journal-title":"J Obes"},{"key":"10.1016\/j.ejim.2015.01.005_bb0055","series-title":"Potassium channels in cardiovascular biology","author":"Archer","year":"2001"},{"issue":"3","key":"10.1016\/j.ejim.2015.01.005_bb0060","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2710.2007.00817.x","article-title":"The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism\u2013or inverse agonism\u2013as potential obesity treatment and other therapeutic use","volume":"32","author":"Xie","year":"2007","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"10.1016\/j.ejim.2015.01.005_bb0065","first-page":"557","article-title":"Narcolepsy: current treatment options and future approaches","volume":"4","author":"Billiard","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.ejim.2015.01.005_bb0070","series-title":"Cochrane database of systematic reviews","article-title":"Long-term pharmacotherapy for obesity and overweight","author":"Padwal","year":"2003"},{"issue":"23","key":"10.1016\/j.ejim.2015.01.005_bb0075","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","article-title":"Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial","volume":"293","author":"Chanoine","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ejim.2015.01.005_bb0080","first-page":"451","article-title":"Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents","volume":"26","author":"Garc\u00eda D\u00edaz","year":"2011","journal-title":"Nutr Hosp"},{"issue":"2","key":"10.1016\/j.ejim.2015.01.005_bb0085","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s13181-012-0213-7","article-title":"Toxicity of weight loss agents","volume":"8","author":"Yen","year":"2012","journal-title":"J Med Toxicol Off J Am Coll Med Toxicol"},{"key":"10.1016\/j.ejim.2015.01.005_bb0090","author":"Drug Safety Communication"},{"issue":"1","key":"10.1016\/j.ejim.2015.01.005_bb0095","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00002018-200831010-00005","article-title":"Orlistat-associated adverse effects and drug interactions: a critical review","volume":"31","author":"Filippatos","year":"2008","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.ejim.2015.01.005_bb0100","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/jpet.107.133348","article-title":"Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization","volume":"325","author":"Thomsen","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.ejim.2015.01.005_bb0105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Multicenter, placebo-controlled trial of lorcaserin for weight management","volume":"363","author":"Smith","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejim.2015.01.005_bb0110","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","article-title":"A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial","volume":"96","author":"Fidler","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ejim.2015.01.005_bb0115","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/oby.2012.66","article-title":"Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study","volume":"20","author":"O'Neil","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.ejim.2015.01.005_bb0120","author":"Belviq (lorcaserin HCl)"},{"issue":"1","key":"10.1016\/j.ejim.2015.01.005_bb0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3","article-title":"Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin","volume":"39","author":"Rothman","year":"2001","journal-title":"Synapse"},{"issue":"1","key":"10.1016\/j.ejim.2015.01.005_bb0135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.gtc.2010.01.001","article-title":"Pharmacologic therapies for obesity","volume":"39","author":"Kaplan","year":"2010","journal-title":"Gastroenterol Clin North Am"},{"issue":"3","key":"10.1016\/j.ejim.2015.01.005_bb0145","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2011.05.014","article-title":"Topiramate-induced weight loss: a review","volume":"95","author":"Verrotti","year":"2011","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.ejim.2015.01.005_bb0150","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"issue":"9774","key":"10.1016\/j.ejim.2015.01.005_bb0155","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejim.2015.01.005_bb0160","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.ejim.2015.01.005_bb0165","author":"FDA"},{"key":"10.1016\/j.ejim.2015.01.005_bb0180","series-title":"Goodman and Gilman's the pharmacological basis of therapeutics","author":"Brunton","year":"2011"},{"issue":"5","key":"10.1016\/j.ejim.2015.01.005_bb0190","first-page":"255","article-title":"Naltrexone SR\/bupropion SR (Contrave)","volume":"36","author":"Ornellas","year":"2011","journal-title":"Pharm Ther"},{"issue":"1","key":"10.1016\/j.ejim.2015.01.005_bb0195","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/11537710-000000000-00000","article-title":"Naltrexone\/bupropion","volume":"10","year":"2010","journal-title":"Drugs R D"},{"issue":"10","key":"10.1016\/j.ejim.2015.01.005_bb0200","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/oby.2002.142","article-title":"Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms","volume":"10","author":"Jain","year":"2002","journal-title":"Obes Res"},{"issue":"7","key":"10.1016\/j.ejim.2015.01.005_bb0205","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/oby.2002.86","article-title":"Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial","volume":"10","author":"Anderson","year":"2002","journal-title":"Obes Res"},{"issue":"9","key":"10.1016\/j.ejim.2015.01.005_bb0210","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/oby.2001.71","article-title":"Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women","volume":"9","author":"Gadde","year":"2001","journal-title":"Obes Res"},{"issue":"11","key":"10.1016\/j.ejim.2015.01.005_bb0215","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1517\/14656560903048959","article-title":"Naltrexone for the treatment of obesity: review and update","volume":"10","author":"Lee","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"9741","key":"10.1016\/j.ejim.2015.01.005_bb0220","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2015.01.005_bb0225","doi-asserted-by":"crossref","unstructured":"Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II). Obes Silver Spring Md.;21(5):935\u201343.","DOI":"10.1002\/oby.20309"},{"issue":"1","key":"10.1016\/j.ejim.2015.01.005_bb0230","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"10.1016\/j.ejim.2015.01.005_bb0235","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2015.01.005_bb0240","author":"FDA"},{"issue":"11","key":"10.1016\/j.ejim.2015.01.005_bb0250","first-page":"746","article-title":"Pharmaceutical approval update","volume":"39","author":"Gohil","year":"2014","journal-title":"Pharm Ther"},{"issue":"9","key":"10.1016\/j.ejim.2015.01.005_bb0255","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nrd3739","article-title":"Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons","volume":"11","author":"Dietrich","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.ejim.2015.01.005_bb0260","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/aps.2011.185","article-title":"Obesity, a health burden of a global nature","volume":"33","author":"Zhang","year":"2012","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"10.1016\/j.ejim.2015.01.005_bb0265","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1242\/dmm.009621","article-title":"Anti-obesity drugs: past, present and future","volume":"5","author":"Rodgers","year":"2012","journal-title":"Dis Model Mech"},{"issue":"2","key":"10.1016\/j.ejim.2015.01.005_bb0270","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11892-010-0096-4","article-title":"Combination drugs for treating obesity","volume":"10","author":"Greenway","year":"2010","journal-title":"Curr Diab Rep"},{"issue":"5","key":"10.1016\/j.ejim.2015.01.005_bb0275","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/MED.0b013e3283304f90","article-title":"Combination therapy for obesity and metabolic disease","volume":"16","author":"Gadde","year":"2009","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.ejim.2015.01.005_bb0280","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.brainres.2010.01.027","article-title":"\u201cWeighing in\u201d on synergy: preclinical research on neurohormonal anti-obesity combinations","volume":"1350","author":"Roth","year":"2010","journal-title":"Brain Res"},{"issue":"9","key":"10.1016\/j.ejim.2015.01.005_bb0285","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nrd3830","article-title":"The pharmaceutical market for obesity therapies","volume":"11","author":"Wong","year":"2012","journal-title":"Nat Rev Drug Discov"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620515000242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620515000242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T04:20:56Z","timestamp":1566274856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620515000242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0953620515000242"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2015.01.005","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug treatment of obesity: Current status and future prospects","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2015.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}